RADNOSTIX INC (INIS) Form 10-Q — Nov 16, 2026
Radnostix reported a nine-month net loss of $3.07 million versus $477,080 a year earlier, as revenue fell 25% to $7.62 million following two voluntary recalls of its Generic Sodium Iodide I-131 and capsule products plus cobalt hot-cell shutdown and isotope supply outages. Cash dropped 58% to $711,288 at quarter-end, though liquidity support came via a $1.0 million Bank of Commerce revolver and a $500,000 related-party note, and the pending $13.5 million sale of its Fluorine Products segment to Nano Nuclear Energy should bring $9 million cash plus $4 million in NNE shares at closing.
Key figures
- Eps
- 0
- Revenue
- 7621744
- Revenue Yoy
- -25% (nine months ended Sep 30, 2026 vs 2025)
- Total Assets
- 16854943
- Cash Position
- 711288
- Shares Outstanding
- 542145510
- Q3 revenue
- 2571035
- New revolver
- 1000000
- Total equity
- 1927221
- Duf6 sale value
- 13500000
- Escrow released
- 500000
- Restricted cash
- 1532733
- Stock price otcqb
- 0.06
- Series c preferred
- 4063000
- Related party notes
- 2120000
- Duf6 cash at closing
- 9000000
- Duf6 restricted shares
- 4000000
- Gross profit nine months
- 4024398
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.